Katherine Stueland Sells 18,006 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 18,006 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08. Following the completion of the sale, the chief executive officer now directly owns 53,140 shares in the company, valued at approximately $4,154,485.20. This trade represents a 25.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total transaction of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $143,456.40.

GeneDx Trading Up 8.3 %

Shares of WGS stock opened at $97.04 on Wednesday. GeneDx Holdings Corp. has a fifty-two week low of $2.80 and a fifty-two week high of $98.87. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $2.67 billion, a P/E ratio of -31.20 and a beta of 2.02. The stock has a 50-day simple moving average of $77.21 and a 200 day simple moving average of $52.15.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million during the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The business’s quarterly revenue was up 44.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.82) earnings per share. On average, sell-side analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Several large investors have recently modified their holdings of WGS. Renaissance Technologies LLC acquired a new stake in shares of GeneDx in the second quarter worth $2,362,000. Chartwell Investment Partners LLC bought a new stake in GeneDx in the 3rd quarter valued at about $1,722,000. Charles Schwab Investment Management Inc. grew its holdings in shares of GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after purchasing an additional 110,666 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in GeneDx in the third quarter valued at approximately $325,000. Finally, Lisanti Capital Growth LLC acquired a new position in GeneDx during the third quarter worth about $1,554,000. 61.72% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. TD Cowen raised their target price on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group raised their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum upped their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company boosted their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.